To further support our drug development, NemaGen will be participating in an NIH I-Corps Program March-April 2023 to speak with various stakeholders to better understand their needs and validate our therapy's value. This program also comes with a $55,000 grant award. Thanks to NCATS for further supporting our efforts to develop therapies treating mastocytosis and other mast cell-related diseases!
NemaGen is honored and excited to announce that we were awarded an NIH Small Business Innovation Research grant. We would like to thank the NIH and NCATS for recognizing the significance and impact of our work focused on treating mastocytosis and other mast cell-related diseases.
Dr. Mark Siracusa spoke at the 24th conference which took place from October 13-20th, 2021
The 25th conference will take place in October 2022
NemaGen's exciting findings have defined a previously unappreciated neuropeptide pathway that prevents unwanted lung inflammation. These studies were recently published in Nature Immunology.